SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Gastric cancer (GC) remains a leading cause of cancer mortality globally.
• MET signaling is crucial in GC initiation, progression, invasiveness, and cancer stemness.
• Current MET-targeted therapies face limitations, including resistance development.

Purpose of the Study:

• To investigate the role of SMYD3 methyltransferase in gastric cancer.
• To explore the interaction between SMYD3 and MET in GC cells.
• To evaluate SMYD3 inhibition as a therapeutic strategy for GC, particularly in combination with MET inhibitors.

Main Methods:

• Investigated the molecular partnership between MET and SMYD3 in GC cells.
• Assessed the impact of SMYD3 pharmacological inhibition on the HGF/MET pathway.
• Utilized cellular analyses in GC models and a 3D cell culture system to evaluate stemness characteristics.
• Tested the synergistic effects of a novel SMYD3 inhibitor (EM127) with MET inhibitors.

Main Results:

• Confirmed MET as a molecular partner of SMYD3 in GC cells.
• Demonstrated that SMYD3 inhibition impacts the HGF/MET downstream signaling pathway.
• Showed that the SMYD3 inhibitor EM127 enhances HGF/MET pathway targeting when combined with MET inhibitors.
• Validated findings in a 3D GC model assessing stemness.

Conclusions:

• SMYD3 is identified as a key molecular partner of MET in gastric cancer.
• Pharmacological inhibition of SMYD3 effectively modulates the HGF/MET pathway.
• Combining SMYD3 inhibitors with MET inhibitors offers a promising synergistic approach to target the HGF/MET pathway in GC.
• SMYD3 represents a potential therapeutic target for improving gastric cancer treatment outcomes.